Work

Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.5062

Authors: Andrew J. Armstrong, Fred Saad, Neal D. Shore, Karim Fizazi, De Phung, Carl Dmuchowski, Mohammad Hirmand, David Forer, Howard I. Scher, Johann S. De Bono

Institutions: Duke University, Duke Cancer Institute, Université de Montréal, Carolina Urologic Research Center, Université Paris-Sud, Institut Gustave Roussy, Astellas Pharma (Netherlands), Astellas Pharma (United States), Medivation, Inc. (United States), Memorial Sloan Kettering Cancer Center, Sidney Kimmel Center for Prostate and Urologic Cancers, Royal Marsden NHS Foundation Trust, Institute of Cancer Research

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4244416132

Cites:

Cited by: 1

Related to: 10